Drug-induced myopathy arising in the setting of immune checkpoint inhibitor therapy can present across a spectrum of severity. When the presentation is mild — characterised by myalgia with low or absent CPK elevation and without severe functional impairment or myasthenia gravis features — a specific management pathway applies.
A patient on immune checkpoint inhibitor therapy who develops myalgia with low or absent CPK elevation, in the absence of severe functional impairment and myasthenia features. This mild clinical course is distinct from more severe forms of immune checkpoint inhibitor-associated myopathy.
This mild presentation responds to a steroid-based intervention. The complete regimen — including specific agent, dosing guidance, and clinical decision points — is available in the structured protocol below.
DOI: 10.3390/biomedicines12050987
In its mild course, with myalgia and low or absent CPK elevation, it responds well to moderate doses of steroids.
View source ↗